Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485051 | 0.85 | ALDH1A1 (0.52) | CYP19A1MAOAMAOBALDH1A1 | |
| SCHEMBL7494852 | 0.85 | ALDH1A1 (0.52) | CYP19A1MAOAMAOBALDH1A1 | |
| SCHEMBL12209754 | 0.81 | FBP1 (0.59) | CYP19A1MAOAMAOBNPSR1NPC1 | |
| SCHEMBL27846179 | 0.78 | CYP19A1 (0.60) | CYP19A1MAOAMAOBNPSR1NPC1 | |
| SCHEMBL27998910 | 0.78 | ALDH1A1 (0.47) | MAOAMAOBNPC1MAPTFBP1 | |
| SCHEMBL12209755 | 0.77 | TP53 (0.41) | CYP19A1MAOAMAOBNPC1FBP1 | |
| SCHEMBL13622505 | 0.76 | NFE2L2 (0.72) | CYP19A1MAOAMAOBNPC1MAPT | |
| SCHEMBL9321479 | 0.75 | TSHR (0.45) | CYP19A1FBP1ALDH1A1 | |
| SCHEMBL29664559 | 0.75 | CYP19A1 (0.86) | CYP19A1MAOAMAOBNPSR1NPC1 | |
| SCHEMBL2774526 | 0.75 | CYP19A1 (0.86) | CYP19A1MAOAMAOBNPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765727-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CYP19A1 2565/4885MAOA 4368/4885MAOB 3848/4885 |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CYP19A1 2565/4885MAOA 4368/4885MAOB 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.